From Computational Chemistry Team to Standalone Company
CompoundAI was founded in 2021 by Dr. Kevin Park and a small team of computational chemists and machine learning engineers who had spent years watching promising drug programs stall - not because the biology was wrong, but because the tools for making chemical decisions were too slow, too siloed, and too dependent on expert intuition that couldn't scale.
The founding insight was straightforward: the data needed to make better compound decisions already exists across published literature, structural databases, and internal assay results. The problem was workflow - integrating those signals at the point of the decision, not weeks later in a committee meeting.
CompoundAI is headquartered in San Francisco's SoMa district, a few blocks from several of the biotech companies and research hospitals we work with.
What We Build
A fully integrated drug discovery platform - target ID, molecular design, ADMET, and clinical translation - designed to be used by scientists, not just IT.
How We Operate
We run our own drug programs using the same platform we offer to partners. The pipeline is proof that the approach works - not a marketing claim.
Who We Work With
Pharmaceutical companies seeking to accelerate internal discovery programs, and academic research groups with validated targets and no path to clinical translation.
San Francisco, CA
CompoundAI is located at 280 Second Street, Suite 200, San Francisco, CA 94105. Our offices are in the South of Market area - central to the Bay Area biotech corridor and close to UCSF's Mission Bay campus.
- 280 Second Street, Suite 200, San Francisco, CA 94105
- [email protected]
- +1 (415) 555-0396
